Published in Curr Opin HIV AIDS on September 01, 2011
Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections. PLoS Pathog (2013) 0.93
HIV-1 Trans Infection of CD4(+) T Cells by Professional Antigen Presenting Cells. Scientifica (Cairo) (2013) 0.93
Construction and immunological evaluation of dual cell surface display of HIV-1 gag and Salmonella enterica serovar Typhimurium FliC in Lactobacillus acidophilus for vaccine delivery. Clin Vaccine Immunol (2012) 0.89
Natural Immunity to HIV: a delicate balance between strength and control. Clin Dev Immunol (2012) 0.87
The role of HIV-1 Vpr in promoting the infection of nondividing cells and in cell cycle arrest. Curr Opin HIV AIDS (2012) 0.85
Influence of dendritic cells on B-cell responses during HIV infection. Clin Dev Immunol (2012) 0.84
Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection. J Immunol (2015) 0.79
Accumulation of functionally immature myeloid dendritic cells in lymph nodes of rhesus macaques with acute pathogenic simian immunodeficiency virus infection. Immunology (2014) 0.77
The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications. PLoS One (2015) 0.76
PolyICLC Exerts Pro- and Anti-HIV Effects on the DC-T Cell Milieu In Vitro and In Vivo. PLoS One (2016) 0.75
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature (2010) 5.45
Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03
Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol (2006) 3.80
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32
Innate sensing of HIV-infected cells. PLoS Pathog (2011) 2.22
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 2.03
HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2007) 2.01
DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol (2011) 1.98
HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol (2010) 1.90
Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. J Virol (2011) 1.85
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A (2011) 1.69
Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood (2010) 1.55
Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest (2011) 1.54
Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood (2010) 1.40
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol (2010) 1.33
HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood (2011) 1.33
Manipulation of dendritic cell function by viruses. Curr Opin Microbiol (2010) 1.29
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A (2010) 1.28
Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine (2009) 1.24
HIV induces maturation of monocyte-derived dendritic cells and Langerhans cells. J Immunol (2006) 1.24
Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol (2008) 1.21
HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur J Immunol (2010) 1.18
High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood (2010) 1.07
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol (2009) 1.07
The inability to disrupt the immunological synapse between infected human T cells and APCs distinguishes HIV-1 from most other primate lentiviruses. J Clin Invest (2009) 1.07
Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis (2009) 1.04
Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology (2009) 1.01
Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J Immunol (2010) 1.01
HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog (2011) 0.99
Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog (2010) 0.98
HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells. Eur J Immunol (2010) 0.97
Contrasting roles for TLR ligands in HIV-1 pathogenesis. PLoS One (2010) 0.97
HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. Blood (2009) 0.96
Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc Natl Acad Sci U S A (2010) 0.96
Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine (2011) 0.96
Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells. J Virol (2009) 0.95
Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. J Leukoc Biol (2011) 0.94
Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol (2007) 0.92
Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine (2010) 0.91
TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. J Immunol (2011) 0.91
J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine (2010) 0.88
Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV- and SHIV-infected macaques. AIDS Res Hum Retroviruses (2009) 0.87
Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr (2009) 0.87
Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog (2009) 0.86
Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. PLoS One (2011) 0.86
A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One (2010) 0.85
Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell Immunol (2010) 0.84
Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS One (2010) 0.82
Loss of NK stimulatory capacity by plasmacytoid and monocyte-derived DC but not myeloid DC in HIV-1 infected patients. PLoS One (2011) 0.82
Accessory cell dependent NK cell mediated PBMC IFN-gamma production is defective in HIV infection. Clin Immunol (2009) 0.81
Role of dendritic cells in HIV-immunotherapy. Curr HIV Res (2010) 0.81
Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model. Immunol Res (2006) 0.80
Immunoregulatory effects of HIV-1 Nef protein. Biofactors (2009) 0.78
Dendritic cell differentiation and maturation in the presence of HIV type 2 envelope. AIDS Res Hum Retroviruses (2009) 0.78
Vaccine candidate targeting dendritic cells enters clinical trial. IAVI Rep (2010) 0.76
HIV-1 and pattern-recognition receptors: a marriage of convenience. Nat Immunol (2010) 0.76
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One (2008) 1.57
Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis (2007) 1.40
[National health research systems in Latin America: a 14-country review]. Rev Panam Salud Publica (2009) 1.39
A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One (2009) 1.35
An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One (2011) 1.35
Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob Agents Chemother (2011) 1.23
Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol (2008) 1.21
Resolution of de novo HIV production and trafficking in immature dendritic cells. Nat Methods (2007) 1.21
A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res Hum Retroviruses (2012) 1.16
Variant-specific tropism of human herpesvirus 6 in human astrocytes. J Virol (2005) 1.15
Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res Hum Retroviruses (2011) 1.14
The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection. J Acquir Immune Defic Syndr (2013) 1.14
R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc Natl Acad Sci U S A (2006) 1.13
Siglecs facilitate HIV-1 infection of macrophages through adhesion with viral sialic acids. PLoS One (2011) 1.10
The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses (2012) 1.04
HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology (2005) 0.99
HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog (2011) 0.99
Local and systemic effects of intranodally injected CpG-C immunostimulatory-oligodeoxyribonucleotides in macaques. J Immunol (2006) 0.96
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog (2008) 0.95
A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo. Antimicrob Agents Chemother (2013) 0.95
Current concepts of HIV transmission. Curr HIV/AIDS Rep (2007) 0.93
A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge. AIDS Res Hum Retroviruses (2013) 0.90
Complete replication cycle and acquisition of tegument in nucleus of human herpesvirus 6A in astrocytes and in T-cells. J Med Virol (2006) 0.87
Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr (2009) 0.87
CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion. Glia (2005) 0.86
Non-specific microbicide product development: then and now. Curr HIV Res (2012) 0.85
A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One (2010) 0.85
Candida albicans-induced DC activation partially restricts HIV amplification in DCs and increases DC to T-cell spread of HIV. J Acquir Immune Defic Syndr (2008) 0.85
MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection. Antimicrob Agents Chemother (2014) 0.84
Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. J Virol (2013) 0.82
Slamming the door on unwanted guests: why preemptive strikes at the mucosa may be the best strategy against HIV. J Leukoc Biol (2006) 0.82
Enabling heterogeneous data integration and biomedical event prediction through ICT: the test case of cancer reoccurrence. Adv Exp Med Biol (2011) 0.80
Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides. AIDS Res Hum Retroviruses (2014) 0.80
In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward? Expert Rev Anti Infect Ther (2013) 0.80
Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection. J Acquir Immune Defic Syndr (2011) 0.80
Current concepts of HIV transmission. Curr Infect Dis Rep (2008) 0.79
Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 0.78
In vivo binding and retention of CD4-specific DARPin 57.2 in macaques. PLoS One (2010) 0.77
Simian immunodeficiency virus interactions with macaque dendritic cells. Adv Exp Med Biol (2013) 0.77
Feline immunodeficiency virus dendritic cell infection and transfer. J Gen Virol (2008) 0.76
Correction: A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3. PLoS Pathog (2016) 0.75
Editorial comment. Curr Opin HIV AIDS (2008) 0.75